Towa Pharmaceutical Co Ltd (4553) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Towa Pharmaceutical Co Ltd (Towa Pharmaceutical) manufactures and sells pharmaceutical products. It develops, manufactures, and distributes generic drugs. The company offers products such as vitamins, antibiotics and other drugs. Towa offers products in the therapeutic areas of gastroenterology, neurology, allergy, bacterial infections, chemotherapy, metabolism, hormone drugs, cardiology and respiratory. The company uses its proprietary technologies such as Ractab, a unique formulation technology for orally disintegrating (OD) tablets. The company also offers drug packaging and testing programs. It offers products in the form of tablets, capsules, injectables, patches, eye drops and others. The company sells its products through medical representatives. It operates through its sales offices in Sapporo, Aomori, Morioka, Sendai, Nagaoka, Nagano, Osaka, Tottori, and Nagasaki, among others. Towa is headquartered in Kadoma, Osaka, Japan.
Towa Pharmaceutical Co Ltd Key Recent Developments
Aug 08, 2024: Towa Pharmaceutical Announces Consolidated Financial Results for the Three Months Ended June 30, 2024
Jun 13, 2024: Listing of Three Ingredients and Seven Items of New Products (New Generics) in the NHI Drug Price Standard
May 22, 2024: Towa Pharmaceutical Notice of Changes in Officers
Feb 15, 2024: Manufacturing and Marketing Approval for Three Ingredients and Eight Items
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Towa Pharmaceutical Co Ltd - Key Facts
Towa Pharmaceutical Co Ltd - Key Employees
Towa Pharmaceutical Co Ltd - Major Products and Services
Towa Pharmaceutical Co Ltd - History
Towa Pharmaceutical Co Ltd - Company Statement
Towa Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Towa Pharmaceutical Co Ltd - Business Description
Geographical Segment: Domestic
Performance
Geographical Segment: Overseas
Performance
R&D Overview
Towa Pharmaceutical Co Ltd - Corporate Strategy
Towa Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Towa Pharmaceutical Co Ltd - Strengths
Towa Pharmaceutical Co Ltd - Weaknesses
Towa Pharmaceutical Co Ltd - Opportunities
Towa Pharmaceutical Co Ltd - Threats
Towa Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Towa Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
Aug 08, 2024: Towa Pharmaceutical Announces Consolidated Financial Results for the Three Months Ended June 30, 2024
Jun 13, 2024: Listing of Three Ingredients and Seven Items of New Products (New Generics) in the NHI Drug Price Standard
May 22, 2024: Towa Pharmaceutical Notice of Changes in Officers
Feb 15, 2024: Manufacturing and Marketing Approval for Three Ingredients and Eight Items
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Towa Pharmaceutical Co Ltd, Key Facts
Towa Pharmaceutical Co Ltd, Key Employees
Towa Pharmaceutical Co Ltd, Major Products and Services
Towa Pharmaceutical Co Ltd, History
Towa Pharmaceutical Co Ltd, Other Locations
Towa Pharmaceutical Co Ltd, Subsidiaries
Towa Pharmaceutical Co Ltd, Key Competitors
Towa Pharmaceutical Co Ltd, Ratios based on current share price
Towa Pharmaceutical Co Ltd, Annual Ratios
Towa Pharmaceutical Co Ltd, Interim Ratios
Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Towa Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Towa Pharmaceutical Co Ltd, Performance Chart (2021 - 2025)
Towa Pharmaceutical Co Ltd, Ratio Charts
Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Year, 2019 to YTD 2025
Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net